Wellington Management Group LLP Raises Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)

Wellington Management Group LLP raised its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 19.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,289 shares of the biopharmaceutical company’s stock after purchasing an additional 22,295 shares during the quarter. Wellington Management Group LLP owned 0.25% of Emergent BioSolutions worth $1,138,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Emergent BioSolutions by 864.7% during the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after buying an additional 1,713,200 shares in the last quarter. American Century Companies Inc. raised its position in shares of Emergent BioSolutions by 240.9% in the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after acquiring an additional 623,201 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after acquiring an additional 316,700 shares during the period. Federated Hermes Inc. boosted its stake in shares of Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after acquiring an additional 253,960 shares in the last quarter. Finally, Marshall Wace LLP grew its position in shares of Emergent BioSolutions by 75.4% during the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after acquiring an additional 233,341 shares during the period. 78.40% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on EBS shares. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark upped their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Friday.

Emergent BioSolutions Stock Down 1.2 %

EBS stock opened at $8.06 on Friday. The stock has a market capitalization of $436.72 million, a P/E ratio of -1.97 and a beta of 1.59. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The firm has a 50-day simple moving average of $9.31 and a 200-day simple moving average of $8.77. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.